These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 11315836

  • 1. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 2. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 3. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y, Matsuda M, DeFronzo RA.
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 5. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 6. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 7. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
    Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.
    Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

  • 9. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 11. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [Abstract] [Full Text] [Related]

  • 12. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.
    Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB.
    Diabetes Care; 1993 Oct; 16(10):1347-55. PubMed ID: 8269792
    [Abstract] [Full Text] [Related]

  • 13. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [Abstract] [Full Text] [Related]

  • 14. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 15. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [Abstract] [Full Text] [Related]

  • 17. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.
    Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H.
    Diabet Med; 1994 Dec; 11(7):685-91. PubMed ID: 7955995
    [Abstract] [Full Text] [Related]

  • 18. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [Abstract] [Full Text] [Related]

  • 19. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.